Vimarsana
Biggest News Aggregation in the World

Page 3 - Rxsight Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rxsight Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rxsight Inc Today - Breaking & Trending Today

Shelley B. Thunen Sells 20,000 Shares of RxSight, Inc. (NASDAQ:RXST) Stock - Vimarsana News

Shelley B. Thunen Sells 20,000 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST – Get Free Report) CFO Shelley B. Thunen sold 20,000 shares of RxSight stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $49.90, for a total value of $998,000.00. Following the completion of the sale, the chief financial officer now directly owns […]

RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Vimarsana News

RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference

ALISO VIEJO, Calif., March 27, 2024 --  RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today...

RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference - Vimarsana News

RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference

ALISO VIEJO, Calif., Feb. 29, 2024 -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today...

RxSight, Inc. to Participate in the 34th Annual Oppenheimer - Vimarsana News

RxSight, Inc. to Participate in the 34th Annual Oppenheimer

ALISO VIEJO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing...

RxSight (NASDAQ:RXST) Price Target Increased to $61.00 by Analysts at Oppenheimer - Vimarsana News

RxSight (NASDAQ:RXST) Price Target Increased to $61.00 by Analysts at Oppenheimer

RxSight (NASDAQ:RXST – Get Free Report) had its target price raised by Oppenheimer from $54.00 to $61.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective points to a potential upside of 8.73% from the company’s previous close. Several other equities analysts […]